Drug Profile
CIM 101 dendritic cell vaccine - CiMaas
Alternative Names: CIM-101 dendritic cell vaccine; DC Xcite; Dendritic cells vaccine - CiMaasLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator CiMaas
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Lung cancer
Most Recent Events
- 06 Oct 2023 Discontinued - Preclinical for Acute myeloid leukaemia in Netherlands (Parenteral) before October 2023 (CiMaas pipeline, October 2023)
- 06 Oct 2023 Discontinued - Preclinical for Lung cancer (Metastatic disease) in Netherlands (Parenteral) before October 2023 (CiMaas pipeline, October 2023)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Lung-cancer(Metastatic disease) in Netherlands (Parenteral)